HoldsUp

Kerry Courneya

Kerry Courneya, PhD, is a researcher studying the effects of exercise and physical activity in cancer care and survivorship. His research evaluates the feasibility, safety, and efficacy of various structured exercise interventions—such as aerobic, resistance, and high-intensity interval training—in patients with cancers including breast, colorectal, prostate, bladder, and endometrial cancer. His publications investigate outcomes related to cancer survival, treatment tolerance, health-related fitness, quality of life, and the economics of exercise interventions.

61 claims checked on air: 1 contradicted 2 overstated 54 supported 4 unverified

What they said on air - overstated

6 citing their own research

0:00:43overstatedlowtheir own paperThe Science of Exercise for Cancer | Kerry Courneya, PhD

Cancer patients who exercise while undergoing chemoradiation therapy are more likely to achieve a complete pathological response prior to surgery.

"And what we found is the patients who exercise while getting this chemoradiation therapy were more likely to have a complete response, meaning the tumors were completely gone prior to having the surgery." (said at 0:00:43)

A Phase II randomized controlled trial in 36 patients with rectal cancer receiving neoadjuvant chemoradiation (the EXERT trial) found that patients assigned to an exercise program had a significantly higher rate of complete or near-complete pathological response compared to usual care (56% vs 18%, p = 0.020). Observational cohort data also associate moderate-to-vigorous physical activity with increased tumor downstaging. However, claiming broadly that exercising cancer patients achieve higher complete response rates overstates the current body of evidence, which is derived from preliminary Phase II trial data and observational studies specifically in rectal cancer; larger Phase III trials are required to establish efficacy.

0:21:26overstatedlowThe Science of Exercise for Cancer | Kerry Courneya, PhD

Low skeletal muscle mass in cancer patients is a critical driver of cancer recurrence and mortality.

"But now there's a lot of research showing that low muscle mass is really the critical thing driving risk of recurrence and death from cancer. So these patients who have low muscle mass or lose muscle mass when they're going through these difficult treatments tend to have the worst outcomes." (said at 0:21:26)

Low skeletal muscle mass (sarcopenia) and muscle wasting during cancer treatment are well-documented prognostic markers associated with poorer clinical outcomes, including reduced overall survival and recurrence-free survival across multiple solid tumors. An umbrella review of 59 meta-analyses encompassing 12 cancer types demonstrated that sarcopenia was associated with worse overall survival (HR = 1.59) and disease-free survival (HR = 1.64) in surgical patients, as well as poorer overall survival (HR = 1.49) in non-surgical therapy. Muscle wasting during neoadjuvant therapy is similarly associated with shorter overall and recurrence-free survival. However, asserting that low muscle mass is 'really the critical thing driving' cancer recurrence and mortality overstates the evidence: the literature comprises observational cohort studies showing associations rather than established causal dominance, the certainty of evidence remains low to very low across most outcomes due to observational confounding by disease stage and cancer cachexia, and the association is not universal across all cancer types (e.g., meta-analyses in breast cancer have found no significant association with recurrence or survival).

Fact-checked episodes

Publications